The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Dec. 22, 2017
Applicant:

Sanofi, Paris, FR;

Inventors:

Britta Göbel, Frankfurt am Main, DE;

Mark Sommerfeld, Frankfurt am Main, DE;

Oliver Boscheinen, Frankfurt am Main, DE;

Thomas Langer, Frankfurt am Main, DE;

Christine Rudolph, Frankfurt am Main, DE;

Andreas Evers, Frankfurt am Main, DE;

Assignee:

SANOFI, Paris, FR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/26 (2006.01); C07K 14/50 (2006.01); A61K 38/18 (2006.01); C07K 14/605 (2006.01); A61K 47/60 (2017.01); A61P 3/10 (2006.01); A61K 38/39 (2006.01); C07K 19/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/26 (2013.01); A61K 38/18 (2013.01); A61K 38/1825 (2013.01); A61K 38/39 (2013.01); A61K 47/60 (2017.08); A61P 3/10 (2018.01); C07K 14/50 (2013.01); C07K 14/605 (2013.01); C07K 19/00 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.


Find Patent Forward Citations

Loading…